Lupus Research Alliance Response to Positive Trial Testing Obinutuzumab (Gazyva®) for Lupus Nephritis
NEW YORK, Nov. 10, 2019 /PRNewswire/ — The Lupus Research Alliance (LRA) is pleased to acknowledge positive results presented by Genentech at the American Society of Nephrology (ASN) and the 2019 ACR/ARP Annual Meeting showing the effectiveness of obinutuzumab (Gazyva®), a type I anti-CD20 monoclonal antibody, in the Phase 2 NOBILITY trial for the most severe […]
Lupus Research Alliance Applauds Phase III Trial Results for Potential Lupus Nephritis Treatment
December 4, 2019 The Lupus Research Alliance congratulates Aurinia Pharmaceuticals on achieving the first positive Phase III trial results for an urgently needed treatment for lupus nephritis. The company’s investigational drug voclosporin showed positive effectiveness and good safety for treating lupus nephritis in combination with standard therapy. “Lupus nephritis is one of the most common […]
Lupus Research Alliance Pleased to Share Positive News about Potential Drug for Lupus Nephritis
NEW YORK, NY. June 11, 2019. The Lupus Research Alliance is pleased to share positive topline results from a Phase 2 clinical study of a potential new treatment for proliferative lupus nephritis, the most severe form of kidney damage caused by lupus. Genentech, a member of the Roche Group, reported that at one year their […]
Lupus Mechanisms and Targets Award (LMTA)
The Lupus Mechanisms and Targets Award ($600,000 for 3 years) supports research focused on the identification and/or investigation of molecular pathways or targets that could lead to new or improved therapies for people with lupus. If you are a researcher and would like to learn more about our funded research please click here.
Lupus Research Alliance Announces 11 Exceptional Recipients of the 2021 Lupus Innovation Award
NEW YORK, NY, December 14, 2021. The Lupus Research Alliance proudly announced today recipients from the U.S. and around the world of the 2021 Lupus Innovation Award which will fund wide ranging areas of research from probing the development and progression of lupus to pointing to potential personalized therapies. The Lupus Innovation Award provides support […]
LRA Pleased to Share GSK’s Benlysta® (belimumab) is First Lupus Nephritis Treatment Approved by FDA
NEW YORK, NY. December 17, 2020. The Lupus Research Alliance (LRA) congratulates GSK on the U.S. Food and Drug Administration (FDA) approval of belimumab (Benlysta®) as the first-ever treatment specifically indicated for lupus nephritis (LN) in adults. Another milestone, this new indication is the only FDA approval of a new lupus treatment since belimumab was […]
People with Lupus and Especially Lupus Nephritis at Higher Risk for Heart Disease, Study Shows
March 17, 2021 People with systemic lupus erythematosus (SLE) are at risk for cardiovascular diseases, and those with lupus nephritis are at greater risk, according to the findings of a new analysis of 20 clinical studies. Results showed that people with SLE are twice as likely to develop cardiovascular disease as healthy people. Their risk […]
LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis
September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […]
Better Lupus Care Reducing Deaths from Lupus Nephritis, Study Shows
April 22, 2019 Results of a study published in Arthritis & Rheumatology shows that end-stage renal disease and mortality due to lupus nephritis is down from 2010-2014. Researchers at Massachusetts General Hospital and Brigham and Women’s Hospital at Harvard Medical School extended an analysis done in 1995 through 2006. Using the national registry of patients […]
Positive Data from Trial of Investigational Treatment KZR-616 for Lupus and Lupus Nephritis
June 3, 2020 Kezar Life Sciences, Inc. today announced updated results from the Phase 1b (Ph1b) portion of MISSION, a study testing the safety and tolerability of KZR-616 for people with systemic lupus erythematosus (SLE) and those who also have lupus nephritis. The drug showed effectiveness in improving seven measures of disease activity. Both of […]